OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
Lenvatinib vs. Sorafenib (HCC)
11 minutes
Posted Apr 24, 2019 at 8:32 pm.
0:00
11:52
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.
Previous
Erdafitinib
Next
Updates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AML
← See all 273 episodes of OncoPharm